

Corporate Profile

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by approximately 200 million patients in 100 markets every day. Headquartered in Israel, Teva is the world's largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has the world-leading innovative treatment for multiple sclerosis as well as late-stage development programs for other disorders of the central nervous system, including movement disorders, migraine, pain and neurodegenerative conditions, as well as a broad portfolio of respiratory products. Teva is leveraging its generics and specialty capabilities in order to seek new ways of addressing unmet patient needs by combining drug development with devices, services and technologies. Teva's net revenues in 2016 were \$21.9 billion. For more information, visit www.tevapharm.com.

Primary IR Contact

Investor Relations

Phone: (215) 591-3034

E-mail:

TevaIRus@tevapharm.com

Recent Headlines

September 19, 2017

Teva and Nuvelution Pharma Partner to Accelerate Development of AUSTEDO® (deutetrabenazine) Tablets for Use in Tourette Syndrome in the United States

September 19, 2017

Teva Completes Amendment to Credit Facilities

September 18, 2017


New Initiative Creates Scalable Solutions to Improve Care of Patients with Multiple Chronic Conditions

Upcoming Events

<i>Date</i>	<i>Title</i>
02-Nov-2017	Q3 2017 Teva Pharmaceutical Industries Ltd. Earnings Conference Call

Analyst Estimates / Ratings

Mean Recommendation: **2.9**



EPS Trend

		Current	30 Days Ago	90 Days Ago
QTR	Sep 17	1.07	1.07	1.25
QTR	Dec 17	1.18	1.18	1.38
QTR	Mar 18	1.03	1.07	1.14
QTR	Jun 18	1.07	1.07	1.17
FY	Dec 17	4.32	4.32	4.76
FY	Dec 18	4.01	4.02	4.69

SEC Filings

Filing Date	Form
09/19/17	6-K
09/19/17	6-K
09/18/17	6-K
09/18/17	6-K

Financial Reports

Date	
05/11/17	First Quarter 2017 Earnings Press Release

Presentations

Date	
08/03/17	Teva Second Quarter Results 2017 Presentation

Corporate Officers

Dr. Yitzhak Peterburg
Interim President and CEO

Iris Beck-Codner
Group EVP, Corporate Marketing & Communications

Dipankar Bhattacharjee
President and Chief Executive Officer, Global Generic Medicines Group Group Executive Vice President, Human Resources

Dr. Hafrun Fridriksdottir
Executive Vice President, President of Global Generics R&D

Dr. Michael Hayden
President of Global R&D and Chief Scientific Officer

Dr. Rob Koremans
President and CEO, Global Specialty Medicines

Michael McClellan
Senior Vice President, Interim Chief Financial Officer

Dr. Carlo de Notaristefani
President and Chief Executive Officer, Global Operations

Mark Sabag
Group Executive Vice President, Human Resources

David M. Stark
Group Executive Vice President, Chief Legal Officer

Nir Baron
Executive Vice President, Chief Internal Auditor